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Abstract
Introduction: The V(D)J rearrangement of B and T cell lymphocytes during the recombination
process, which is essential for the development of normal immune system function, depends critically
on the presence of the recombination activating enzymes, RAG1 and RAG2. Mutations in RAG1 or
RAG2 can lead to a spectrum of disorders, ranging from typical B-T-severe combined
immunodeficiency to Omenn’s syndrome.
Case presentation: A two-month-old Saudi baby girl presented with fever, respiratory distress due
to bronchiolitis, exfoliative erythroderma and a family history of childhood death within the first few
months of life in two of her sisters who had had a similar clinical presentation to her own.
Immunological work-up revealed an absence of circulating B lymphocytes, whereas various numbers
of activated T lymphocytes were present in the peripheral blood and in the skin.
Conclusion: In this case, mutation analysis of the recombination activating genes RAG1 or RAG2
revealed a homozygous missense (c.1299G>A) mutation in the RAG1 gene. This is the first report in
the literature linking a homozygous R396H mutation in the RAG1 gene with presentation of Omenn’s
syndrome.
Introduction
Omenn’s syndrome(MIM603554) is anautosomal recessive
form of severe combined immunodeficiency (SCID) char-
acterizedbyearly-onset generalizedexfoliative erythroderma,
desquamation, alopecia, chronic diarrhea, failure to thrive,
lymphadenopathy, hepatosplenomegaly and elevated IgE
levels. In early infancy, patients with SCID develop poten-
tially life-threatening recurrent infections that may be caused
by common bacterial, fungal, or viral infections.
Laboratory findings reveal a characteristic hypereosino-
philia and hypogammaglobulinemia. However, IgE serum
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levels are increased paradoxically in the absence of
detectable B lymphocytes in peripheral blood and in
skin and lymph node tissues [1,2].
Both B and T cell lymphocytes undergo the recombination
process of V(D)J rearrangement that is essential for the
development of normal immune function, and the
recombination activating enzymes RAG1 and RAG2 play
a crucial role in this recombination [3]. Molecular genetic
studies have been focused on elucidating the molecular
basis of the B-T- subgroup of SCID that is associated with
Omenn’s syndrome.
Mutation analysis studies involving SCID and Omenn’s
syndrome have identified mutations in RAG1 and RAG2
[1] that may show differing clinical presentations depend-
ing on the type of mutation. When mutations in the
recombinase genes RAG-1 and RAG-2 have been explored,
homozygous and heterozygous mutations have been
found. In contrast to T cell negative (T−), B cell negative
(B−), and natural killer cell positive (NKC+) SCID, in
which RAG-1 and RAG-2mutations affect the active core of
the gene, homozygous mutations affecting the active core
have not been observed in Omenn’s syndrome. Approxi-
mately half of the mutations are missense mutations,
while the remainder are nonsense, deletion, frameshift,
duplication, and splice mutations[1,4].
Here, we describe a Saudi female infant who was the
8th child of first-degree relative parents (Figure 1). Family
history was positive for two early infantile deaths with
clinical manifestations consistent with Omenn’s syn-
drome, as shown in this patient. The patient was shown
to be a homozygote for mutations in the RAG1 gene.
Case presentation
Our case is thatof a two-month-old Saudi female (Figure1).
The family has a history of two early infantile deaths
from undiagnosed recurrent chest infections associated
with generalized skin erythema. Pregnancy and delivery
were uncomplicated. Birth weight was 3500 g. At the age
of 2 weeks, the infant presented with generalized scaly
erythroderma associated with persistent fever and later
developed pneumonia. There was no lymphadenopathy
and no hepatosplenomegaly. Subsequently, she devel-
oped protracted diarrhea and failure to thrive. The
patient had elevated numbers of circulating white blood
cells and low hemoglobin (Hb). Flow cytometry showed
a critically low (absent) B-cell count with a predomi-
nance of T cells (82%) that showed high memory
(CD45RO) and activation (CD25) expression. There
were normal levels of natural killer cells with normal
expression of gamma/delta TCR cells, but no detectable
CD19+ or CD20+ B-cells. Both CD4 and CD8 T cells
were significantly suppressed; only 21% of CD4 and
33% of CD8 were activated in response to phytohema-
glutinine (PHA). Humoral immunity was also abnormal,
with elevated serum IgE levels. The nature of the T cells
and the remarkable absence of the circulating B cells
raised the possibility of a defect in immunoglobulin
gene recombination. The histopathological finding of
the skin biopsy revealed atypical lymphoid cells that are
occasionally noted in the dermal infiltrate. The immu-
nostaining showed that most of the lymphoid cells
infiltrating the dermis were of T cell type. The staining of
S-100 (polyclonal) was negative in the target cell,
suggesting an absence of normal follicles. RAG mutation
analysis of our patient revealed a homozygous missense
mutation (c.1299G>A) in the RAG1 gene leading to
replacement of the normal Arginine (R) amino acid to
Histidine (H) at the 396 codon position (R396H) of the
resultant normal protein.
This is the first report in the literature showing a homo-
zygous R396H mutation in the RAG1 gene presenting
itself with features of Omenn’s syndrome. Our patient
presented with some of the typical clinical manifestations
of Omenn’s syndrome that are characterized by a general-
ized early-onset of exfoliative erythroderma, persistent
infection, alopecia, elevated IgE level and elevated white
blood count due to lymphocytosis. Skin biopsy showed
autologous T-cell infiltration and the absence of
a germinal center, which is consistent with histopatholo-
gical findings in Omenn’s syndrome [5].
The patient had no B cells, and the majority of her WBCs
were T cells that had a very high expression of the CD45RO
memory marker and IL-2R (CD25). Both CD4 and CD8 T
cells showed significantly reduced capacity to respond to
PHAstimulation.Villa et al. (2001)andCorneoet al. (2001)
described patients who showed a nearly complete absence
of B cells, reduced number of T cells, and normal NK.
The RAG mutation analysis in our patient revealed
a homozygous missense mutation (c.1299G>A) in
the RAG1 gene, which led to the replacement of the
Figure 1. Pedigree of the Saudi family with Omenn’s
syndrome. Blackened symbol indicate proband. Diagonal lines
across symbols indicate deceased individuals.
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normal Arginine amino acid to Histidine at the 396 codon
position of the resultant normal protein. This mutation
has been previously reported in association with Omenn’s
syndrome in which this missense mutation (c.1299G>A)
was detectable in a patient who was heterozygous for the
allele; the mutation was associated with a protein-
truncating mutation [4,6].
The location of this missense mutation (i.e., R396H) is
within the RAG1 homeodomain region, which is respon-
sible for the recognition of and binding to the nonamer
motif of the recombination signal sequence (RSS) [6].
Biochemical analysis performed on classic Omenn’s
syndrome cases that are harboring a one-allele missense
mutation in their RAG1 gene maintained partial V(D)J
recombination activity, which accounted for the genera-
tion of detectable numbers of activated, anergic, oligoclo-
nal T-lymphocytes [6]. In our case, the lack of circulating
B cells, together with oligoclonal expansion of T cells,
raised the possibility of RAG deficiency despite the clinical
presentation. We suspect that the presence of a homo-
zygous R396Hmutation in our patient likely destroyed the
function of the RAG1 protein and hence impaired the
recombination activity that may be associated directly or
indirectly with impairment in B cell immunity. The result
of this may be an increased occurrence of life-threatening
infections, and, without proper treatment, the condition
may lead to death within the first year of life. This explains
the death of our patient's two sisters who presented with
symptoms consistent with Omenn’s syndrome during
their few months of life.
Conclusion
This is the first report in the literature showing a homo-
zygous R396H mutation in the RAG1 gene being linked to
features of Omenn’s syndrome. Consanguineous mar-
riages increase the risk of autosomal recessive disorders.
Therefore, choosing to undergo premarital screening,
prenatal diagnosis and genetic counseling should be an
important consideration for family future planning.
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